PREFACE: The evidence supports a deliberately conservative stance. The strongest data are prognostic associations from large cohorts: in UK Biobank (n≈472,000), shorter LTL carried a modest all-cause mortality increase (HR 1.08 per SD) with larger organ-specific signals, and epigenetic clocks, particularly GrimAge and DunedinPACE, predict incident COPD, type 2 diabetes, ischaemic heart disease and mortality across cohorts. Crucially, LTL and epigenetic age are independent and weakly correlated, so they are not interchangeable. 

Three findings drive the caution flagged throughout: (1) the only RCT using these as outcomes (CALERIE) moved DunedinPACE by just 2–3% and did not meet its primary endpoint, with no change in PhenoAge/GrimAge; (2) Mendelian randomisation shows a genuine cancer–cardiovascular trade-off, so “longer telomeres = healthier” is incorrect; and (3) biological reliability of clocks is low–moderate despite good technical reproducibility, undermining single-timepoint individual decisions. No regulator (NICE, MHRA, FDA, EMA) endorses these as clinical tests, and telomerase-activating supplements rest on in-vitro/animal data plus one biomarker-only RCT (TA-65) with unresolved oncological safety. Accordingly, the summary positions testing as adjunctive/consented or research-grade, and explicitly warns against inferring hard clinical benefit from surrogate movement. The telomere to disease trade-off is the single most counterintuitive point for patients and clinicians. For example, a study from the Telomeres Mendelian Randomization Collaboration (JAMA Oncology) showed how genetically longer telomeres raise the odds of several cancers while lowering the odds of coronary heart disease and other degenerative conditions.

A central caveat governs the whole document: epigenetic and telomere metrics are prognostic surrogate biomarkers, and no outcome trial has yet shown that testing them, or acting on the results, improves hard clinical endpoints.

 

1. Scope

What is covered:

– DNA methylation “epigenetic clocks” (Horvath/pan-tissue, Hannum, PhenoAge, GrimAge/PCGrimAge, DunedinPACE) and DNAm-derived surrogates (DNAmTL).[1][2][3]

– Leukocyte telomere length (LTL) measured by qPCR or flow-FISH.[4][5]

– Their role as adjunctive biological-age assessment tools within a longevity clinic, alongside (never replacing) conventional primary and secondary care and validated risk tools (e.g. QRISK).

What is NOT covered:

– Diagnostic genetic/germline testing for monogenic telomere biology disorders (dyskeratosis congenita, short-telomere syndromes, idiopathic pulmonary fibrosis pedigrees)—these require clinical genetics referral.

– Proteomic, glycomic, inflammatory (iAge) or multi-omic clocks except in passing.[2]

– Telomerase-activating drugs/supplements as therapy (discussed only to define evidence limits).[6][7]

Overarching position: These tests are not guideline-endorsed for routine clinical use by NICE, MHRA, FDA or EMA. They are best regarded as research-grade or experimental tools offered as adjunctive care with explicit informed consent.[8][9]

2. Background and pathophysiology

Biological rationale

– Ageing can be described by molecular hallmarks; telomere attrition and epigenetic alteration are two of these and are the most commonly used to estimate human biological age.[10]

– Telomeres are repetitive DNA-protein caps that shorten with each mitotic division (“end-replication problem”), accelerated by oxidative stress and inflammation; critically short telomeres trigger senescence or apoptosis. LTL therefore behaves as a mitotic/proliferative clock.[5][11]

– Epigenetic clocks are weighted DNA methylation values at specific CpG sites. First-generation clocks (Horvath, Hannum) were trained on chronological age; second-generation clocks (PhenoAge, GrimAge) were trained on mortality/clinical phenotypes; DunedinPACE was trained on the longitudinal rate of decline (“speedometer” vs “odometer”).[2][12]

Key point — the two measure different things: LTL and epigenetic age correlate only weakly and are independent predictors of chronological age and mortality; they capture largely distinct aspects of ageing (mitotic vs multi-system phenotypic).[13][14][4] DNAmTL (a methylation surrogate for telomere length) does not actually measure telomere length but can out-predict measured LTL for some outcomes.[15]

Preclinical / mechanistic-only evidence (low weight — do not use for clinical decisions):

– Telomerase (TERT) re-expression lengthens telomeres and extends lifespan in mice and cell models, with proposed extra-telomeric roles in oxidative-stress protection and metabolism.[16][17]

– Epitalon and various “natural” telomerase activators (TA-65, Astragalus/Centella extracts, oleanolic acid) increase telomerase activity or telomere length in vitro.[18][19]

– These data establish biological plausibility only and must not be presented to patients as clinical benefit.

3. Evidence base and grading

Types of evidence available

– Large prospective cohorts with hard endpoints (UK Biobank, n≈472,000; Lothian, Generation Scotland, LURIC, BASE-II).[14][5][20][3]

– Mendelian randomisation for causal inference on telomere length and disease.[21]

– One RCT (CALERIE, n=220) using DNAm clocks as outcomes of an intervention.[22]

– Reliability/methodological studies.[23][24]

– Meta-analysis of exercise RCTs with telomere/telomerase endpoints.[25]

There are no RCTs demonstrating that performing epigenetic or telomere testing changes patient-relevant outcomes.

GRADE-style certainty and strength of recommendation by outcome

Outcome / claim	Evidence base	Certainty (GRADE)	Recommendation
Shorter LTL is associated with higher all-cause mortality	UK Biobank (HR 1.08 per SD) + prior meta-analysis; consistent, large, precise; residual confounding/indirectness	Moderate	Reasonable prognostic marker; conditional [5], [11]
Epigenetic age acceleration (esp. GrimAge/DunedinPACE) predicts mortality & incident age-related disease	Multiple large cohorts (Lothian, Generation Scotland); consistent	Moderate	Conditional (prognostic enrichment only) [3], [14]
Longer telomeres are uniformly protective (“longer = healthier”)	MR shows trade-off: lower CVD risk but higher risk of several cancers (e.g. glioma)	Moderate (against the simplistic claim)	Recommend against interpreting long telomeres as unambiguously good [21]
Telomere/epigenetic testing improves clinical outcomes when used to guide care	No outcome trials	Very low	Only in research [9], [24]
Interventions that move these biomarkers produce commensurate clinical benefit	CALERIE moved DunedinPACE by 2–3% (small; primary endpoint not met); PhenoAge/GrimAge unchanged	Low	Only in research; do not infer hard benefit from surrogate change [12], [22]
Biomarker reproducibility supports individual-level decisions	Technical reliability good for PC-clocks; biological reliability low–moderate; LTL–clock agreement weak	Low–Moderate	Interpret single readings cautiously; prefer PC-based clocks [23], [24]

4. Patient selection and indications

Who might reasonably be offered testing (adjunctive, consented):

– Middle-aged adults (approx. 40–65) with elevated cardiometabolic risk seeking to contextualise risk and reinforce lifestyle change—recognising that validated tools (QRISK, lipids, HbA1c, BP) remain primary.[8][1][5]

– Motivated adults wanting a longitudinal biological-age track to monitor response to lifestyle programmes, ideally within a registry.[1][2]

– Research participants in trials/registries evaluating geroprotective interventions.[22][24]

Exclusion / high-risk groups (avoid or specialist input first):

– Personal or strong family history suggesting a short-telomere syndrome (early greying, pulmonary fibrosis, bone marrow failure, unexplained cytopenias/cirrhosis) → refer to clinical genetics/haematology, not commercial testing.[5]

– Active or recent malignancy, or high cancer anxiety — given the telomere–cancer trade-off, results may mislead or distress.[21]

– Acute illness, recent infection, high physiological stress — these transiently perturb clocks and LTL, reducing validity.[23]

– Patients likely to make unsupervised harmful decisions (e.g. purchasing telomerase-activating supplements) based on results.

Regulatory and ethical status:

– Off-label / non-guideline / no on-label indication. No regulator endorses these as clinical tests.

– Position: adjunctive care with explicit informed consent, or within a research/registry framework. Consent must state the tests are surrogate biomarkers of uncertain individual-level clinical utility.[8][9]

5. Assessment and baseline work-up

Pre-test assessment

– Full history: cardiometabolic risk factors, smoking, alcohol, physical activity, sleep, psychosocial stress, family history (see red flags above).[26][5]

– Examination: BP, BMI/waist, frailty screen in older adults.

– Conventional risk stratification remains the backbone: QRISK3, lipid profile, HbA1c, renal/liver function, FBC.

Baseline biomarker documentation (if testing is undertaken)

– Record which assay and platform was used (qPCR vs flow-FISH for LTL; EPIC/450K array and specific clock algorithm for methylation) — results are not interchangeable across methods.[4][23]

– Prefer PC-based clocks (PCGrimAge, SystemsAge) where available, given superior technical robustness.[23]

– Document standardised pre-analytical conditions (fasting status, time of day, recent illness/exercise) to limit biological noise on repeat testing.[23]

Risk stratification for benefit vs harm

– Likely low harm/low yield: healthy, low-risk adults wanting reassurance — set expectations that results rarely change management.

– Potential value: higher-risk adults where an accelerated result may reinforce evidence-based lifestyle/pharmacological risk reduction.

– Higher harm potential: cancer-anxious or short-telomere-syndrome-suspect patients (see §4).

6. Practical implementation

Test selection (robust vs cautious)

– Reasonable, better-validated: GrimAge/PCGrimAge and DunedinPACE (strongest mortality/incident-disease prediction and better reliability); LTL by a single consistent assay.[2][3][23]

– Weaker for individual use: first-generation Horvath/Hannum clocks (track chronological age but weaker for health outcomes); single qPCR LTL (assay variability).[24]

Retest cadence

– Because annual telomere attrition is small (~48–67 bp/yr) and single-timepoint biological noise is substantial, intervals shorter than 12 months are not informative; 12–24 months is more defensible.[14][23][27]

Downstream interventions — evidence tiers (state tier explicitly to patients):

– Supported by robust human data (recommend regardless of testing): smoking cessation, Mediterranean-style diet, regular aerobic/interval exercise, weight management, alcohol moderation. Exercise RCT meta-analysis shows maintained TL and increased telomerase activity, particularly aerobic training ≥16 weeks.[25][28][26]

– RCT evidence on the biomarker only, not on hard outcomes: sustained caloric restriction slowed DunedinPACE by ~2–3% (CALERIE).[22]

– Extrapolated / caution / no robust human outcome data — do NOT recommend as therapy: telomerase-activating supplements (TA-65, Epitalon, botanical activators). TA-65 lengthened LTL in one RCT but with no clinical-outcome data and unresolved oncological-safety questions given the telomere–cancer trade-off.[6][21][18]

7. Monitoring, safety and follow-up

Nature of risk: the test itself is a venous blood draw—physically low-risk. The principal harms are informational and behavioural: misinterpretation, false reassurance, anxiety, overdiagnosis cascades, and adoption of unproven/unsafe interventions.[9][21]

Monitoring plan

– Track conventional parameters that actually drive management (BP, lipids, HbA1c, weight, fitness).

– If repeating biomarkers, use the same assay/platform, standardised conditions, and interpret change against known measurement error rather than treating small shifts as real.[23]

Timepoints

– Short term (0–3 months): focus on evidence-based lifestyle/risk-factor actions, not retesting.

– Medium term (12 months): earliest sensible biomarker retest.

– Long term (≥24 months): longitudinal trend interpretation, ideally within a registry.

Actions on abnormal findings

– “Accelerated” biological age → reinforce guideline-based cardiometabolic risk reduction and review conventional risk factors; do not initiate unproven pharmacotherapy.

– Findings suggesting a short-telomere syndrome (extreme short LTL with supportive phenotype/family history) → refer to clinical genetics/haematology/respiratory as appropriate.[5]

Interactions/comorbidities: acute infection, systemic inflammation, recent vigorous exercise, and changes in leukocyte composition all affect readings and should be accounted for when interpreting.[10][23]

Special populations

– Pregnancy/breastfeeding: no role; not indicated.

– Frailty/older adults: longitudinal biomarker prediction of functional decline was not confirmed in BASE-II/GendAge, so results should not drive management in frail patients.[29]

– Renal/hepatic impairment, extremes of age: interpret cautiously; evidence base is largely middle-aged/older cohorts.

8. Contraindications and cautions

Absolute contraindications: none physiologically, but testing is inappropriate/should not be offered where results would be used to justify unlicensed telomerase-activating therapy, or as a substitute for indicated conventional investigation of symptoms.

Relative contraindications / specialist advice needed:

– Suspected heritable telomere biology disorder (refer, do not use commercial testing).[5]

– Active malignancy or high cancer anxiety (telomere–cancer trade-off).[21]

– Significant health anxiety or unrealistic expectations.

Situations where harm likely outweighs benefit: using single-timepoint results to make individual prognostic pronouncements or to start/stop treatments—biological reliability is too low to support this.[23][24]

9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors

– Recommendation: Consider testing as an adjunct (conditional/weak) — only if it will reinforce, not replace, guideline care.[1][5]

– Assessment: full cardiometabolic work-up + QRISK3.

– Shared decision-making: explain surrogate status; results unlikely to change evidence-based management.

– Initiation: GrimAge/DunedinPACE ± single-assay LTL, standardised conditions.

– Monitoring: prioritise BP/lipids/HbA1c/fitness; retest biomarker at ≥12 months if at all.

– Escalate/stop: if biomarker anxiety develops, discontinue testing; refer if short-telomere phenotype emerges.

Scenario B — Older, frail patient with multimorbidity

– Recommendation: Avoid routine testing (weak). Longitudinal data show these markers did not predict functional decline in older adults.[29]

– Focus on validated frailty assessment and comprehensive geriatric management.

Scenario C — Patient already under specialist care, wanting testing as an adjunct

– Recommendation: Restrict to research/registry or offer only with explicit consent; must not interfere with specialist-directed treatment.[9][24]

– Coordinate with the treating specialist; document that testing is exploratory.

– Never adjust specialist therapy on the basis of clock/LTL results.

10. Research gaps and future directions

– No outcome trials: whether testing (and acting on it) improves morbidity/mortality is untested — the key gap.[9][24]

– Surrogate validity: biomarker change (e.g. CALERIE DunedinPACE) has not been shown to translate into hard clinical benefit at the individual level.[22]

– Reliability: biological (within-person) reliability is low–moderate; standardisation of assays, platforms and reference ranges is lacking.[8][23]

– Causality/trade-offs: MR indicates telomere length has opposing effects on cancer vs cardiovascular disease—”longer is better” is unsafe as a clinical goal.[21]

– Priority questions: which clock(s) best guide intervention; minimum meaningful change vs measurement error; performance in frailty and diverse ancestries; safety of telomerase-activating interventions.

– Ideal setting for current practice: well-designed trials and prospective registries, not routine unmonitored clinical use.

References

1. Epigenetic Clocks and EpiScore for Preventive Medicine: Risk Stratification and Intervention Models for Age-Related Diseases. Yamada H. Journal of Clinical Medicine. 2025;14(10):3604. doi:10.3390/jcm14103604.
2. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
3. Epigenetic Measures of Ageing Predict the Prevalence and Incidence of Leading Causes of Death and Disease Burden. Hillary RF, Stevenson AJ, McCartney DL, et al. Clinical Epigenetics. 2020;12(1):115. doi:10.1186/s13148-020-00905-6.
4. Telomere Length and Epigenetic Clocks as Markers of Cellular Aging: A Comparative Study. Pearce EE, Alsaggaf R, Katta S, et al. GeroScience. 2022;44(3):1861-1869. doi:10.1007/s11357-022-00586-4.
5. Association of Telomere Length With Risk of Disease and Mortality. Schneider CV, Schneider KM, Teumer A, et al. JAMA Internal Medicine. 2022;182(3):291-300. doi:10.1001/jamainternmed.2021.7804.
6. A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study. Salvador L, Singaravelu G, Harley CB, et al. Rejuvenation Research. 2016;19(6):478-484. doi:10.1089/rej.2015.1793.
7. Telomerase Activation in the Treatment of Aging or Degenerative Diseases: A Systematic Review. Prieto-Oliveira P. Molecular and Cellular Biochemistry. 2021;476(2):599-607. doi:10.1007/s11010-020-03929-x.
8. Integrating Biological Age, Epigenetic Clocks, and Telomere Length in Precision Nutrition Strategies for Chronic Disease Management: Potential Frameworks and Ongoing Challenges. Carvalho BG, Ribeiro AA, da Mota JCNL, Carvalho LM, Nicoletti CF. Nutrition Research (New York, N.Y.). 2025;140:135-160. doi:10.1016/j.nutres.2025.06.010.
9. From Longevity Genetics to Precision Interventions: Integrating Nutrigenomics and Epigenetic Mechanisms of Ageing. Pîrlog LM, Cătană A, Pitforodeschi AD, et al. Genes. 2026;17(6):681. doi:10.3390/genes17060681.
10. Biological Versus Chronological Aging: JACC Focus Seminar. Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Journal of the American College of Cardiology. 2020;75(8):919-930. doi:10.1016/j.jacc.2019.11.062.
11. Cardiovascular Aging and Longevity: JACC State-of-the-Art Review. Pietri P, Stefanadis C. Journal of the American College of Cardiology. 2021;77(2):189-204. doi:10.1016/j.jacc.2020.11.023.
12. Cut Calories, Lengthen Life Span? Randomized Trial Uncovers Evidence That Calorie Restriction Might Slow Aging, but Questions Remain. Rubin R. JAMA. 2023;329(13):1049-1050. doi:10.1001/jama.2023.2437.
13. Epigenetic Clock and Relative Telomere Length Represent Largely Different Aspects of Aging in the Berlin Aging Study II (BASE-II). Vetter VM, Meyer A, Karbasiyan M, et al. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2019;74(1):27-32. doi:10.1093/gerona/gly184.
14. The Epigenetic Clock and Telomere Length Are Independently Associated With Chronological Age and Mortality. Marioni RE, Harris SE, Shah S, et al. International Journal of Epidemiology. 2018;45(2):424-432. doi:10.1093/ije/dyw041.
15. “Epigenetic clocks”: Theory and applications in human biology. Ryan CP. American Journal of Human Biology : The Official Journal of the Human Biology Council. 2021;33(3):e23488. doi:10.1002/ajhb.23488.
16. Canonical and Extra-Telomeric Functions of Telomerase: Implications for Healthy Ageing Conferred by Endurance Training. Denham J. Aging Cell. 2023;22(6):e13836. doi:10.1111/acel.13836.
17. Telomerase and the Aging Cell: Implications for Human Health. Fossel M. JAMA. 1998;279(21):1732-5. doi:10.1001/jama.279.21.1732.
18. Epitalon Increases Telomere Length in Human Cell Lines Through Telomerase Upregulation or ALT Activity. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Biogerontology. 2025;26(5):178. doi:10.1007/s10522-025-10315-x.
19. Discovery of Potent Telomerase Activators: Unfolding New Therapeutic and Anti-Aging Perspectives. Tsoukalas D, Fragkiadaki P, Docea AO, et al. Molecular Medicine Reports. 2019;20(4):3701-3708. doi:10.3892/mmr.2019.10614.
20. Telomere Length and Mortality in the Ludwigshafen Risk and Cardiovascular Health Study. Pusceddu I, Kleber M, Delgado G, et al. PloS One. 2018;13(6):e0198373. doi:10.1371/journal.pone.0198373.
21. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. Telomeres Mendelian Randomization Collaboration, Haycock PC, Burgess S, et al. JAMA Oncology. 2017;3(5):636-651. doi:10.1001/jamaoncol.2016.5945.
22. Effect of Long-Term Caloric Restriction on DNA Methylation Measures of Biological Aging in Healthy Adults From the CALERIE Trial. Waziry R, Ryan CP, Corcoran DL, et al. Nature Aging. 2023;3(3):248-257. doi:10.1038/s43587-022-00357-y.
23. Biological Versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response. Sehgal R, S Borrus D, Gonzalez J, et al. Aging Cell. 2026;25(8):e70635. doi:10.1111/acel.70635.
24. Eleven Telomere, Epigenetic Clock, and Biomarker-Composite Quantifications of Biological Aging: Do They Measure the Same Thing?. Belsky DW, Moffitt TE, Cohen AA, et al. American Journal of Epidemiology. 2018;187(6):1220-1230. doi:10.1093/aje/kwx346.
25. Exercise Delays Aging: Evidence From Telomeres and Telomerase -a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sun L, Zhang T, Luo L, et al. Frontiers in Physiology. 2025;16:1627292. doi:10.3389/fphys.2025.1627292.
26. Nutrients, Foods, Dietary Patterns and Telomere Length: Update of Epidemiological Studies and Randomized Trials. Freitas-Simoes TM, Ros E, Sala-Vila A. Metabolism: Clinical and Experimental. 2016;65(4):406-15. doi:10.1016/j.metabol.2015.11.004.
27. Increased Telomerase Activity and Comprehensive Lifestyle Changes: A Pilot Study. Ornish D, Lin J, Daubenmier J, et al. The Lancet. Oncology. 2008;9(11):1048-57. doi:10.1016/S1470-2045(08)70234-1.
28. Differential Effects of Endurance, Interval, and Resistance Training on Telomerase Activity and Telomere Length in a Randomized, Controlled Study. Werner CM, Hecksteden A, Morsch A, et al. European Heart Journal. 2019;40(1):34-46. doi:10.1093/eurheartj/ehy585.
29. Relationship Between 5 Epigenetic Clocks, Telomere Length, and Functional Capacity Assessed in Older Adults: Cross-Sectional and Longitudinal Analyses. Vetter VM, Kalies CH, Sommerer Y, et al. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2022;77(9):1724-1733. doi:10.1093/gerona/glab381.